Record-Breaking Price Movement
On 2 December 2025, Fredun Pharmaceuticals touched an intraday peak of Rs.1999, setting a fresh 52-week and all-time high for the stock. This milestone comes amid a five-day consecutive gain period, during which the stock has delivered returns of 11.21%. The day’s performance saw the stock rise by 2.43%, outperforming the Sensex which recorded a decline of 0.22% on the same day. Furthermore, Fredun Pharmaceuticals outpaced its sector by 2.53% today, underscoring its relative strength in the Pharmaceuticals & Biotechnology space.
Consistent Upward Momentum Across Timeframes
Examining the stock’s trajectory over various time horizons reveals a pattern of robust appreciation. Over the past week, the stock has shown an 11.14% gain compared to the Sensex’s 1.02%. The one-month period highlights a more pronounced movement, with Fredun Pharmaceuticals registering a 29.03% increase against the Sensex’s 1.80%. The three-month performance further accentuates this trend, with the stock advancing by 67.31%, significantly outstripping the Sensex’s 6.60% rise.
Longer-term data also reflects substantial value creation. Over the last year, Fredun Pharmaceuticals has recorded a 152.11% return, dwarfing the Sensex’s 6.48% gain. Year-to-date figures show an even stronger performance, with the stock appreciating by 169.38% compared to the Sensex’s 9.36%. Over three and five years, the stock has delivered 50.98% and 596.84% returns respectively, both surpassing the corresponding Sensex returns of 35.92% and 91.52%. These figures illustrate the company’s ability to generate market-beating returns consistently over multiple periods.
Technical Indicators Confirm Strength
Fredun Pharmaceuticals is currently trading above its key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained positive momentum and a strong underlying trend supporting the stock’s price levels.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Financial Performance Underpinning the Rally
Fredun Pharmaceuticals’ recent financial results provide context for its market performance. The company reported net sales of Rs.145.30 crores in the latest quarter, reflecting a growth rate of 35.35%. Operating profit has expanded at an annual rate of 55.03%, while net profit has shown a notable increase of 127.87% in the same period. The quarterly profit after tax (PAT) stood at Rs.9.73 crores, reinforcing the company’s positive earnings trajectory.
Operating profit to interest ratio reached a high of 2.89 times, indicating a comfortable coverage of interest expenses by operating earnings. These financial metrics highlight the company’s capacity to generate healthy profits and maintain operational efficiency.
Valuation and Capital Efficiency
Fredun Pharmaceuticals exhibits an attractive valuation profile with a return on capital employed (ROCE) of 20.2%. The enterprise value to capital employed ratio stands at 3.4, suggesting efficient utilisation of capital resources. Compared to its peers, the stock is trading at a discount relative to average historical valuations, which may reflect market perceptions of the company’s scale and sector positioning.
Over the past year, while the stock price has appreciated by 152.11%, profits have risen by 63.5%, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.5. This ratio indicates a valuation that is moderate relative to the company’s earnings growth rate.
Market Position and Shareholder Composition
Fredun Pharmaceuticals operates within the Pharmaceuticals & Biotechnology sector, a segment characterised by innovation and regulatory complexities. Despite the company’s size and performance, domestic mutual funds currently hold no stake in the stock. This absence of mutual fund ownership may reflect a cautious stance or differing evaluation criteria among institutional investors.
Fredun Pharmaceuticals caught your attention? Explore our comprehensive research report with in-depth analysis of this micro-cap Pharmaceuticals & Biotechnology stock – fundamentals, valuations, financials, and technical outlook!
- - Comprehensive research report
- - In-depth micro-cap analysis
- - Valuation assessment included
Summary of Market-Beating Returns
Fredun Pharmaceuticals has demonstrated market-beating performance across multiple timeframes. The stock’s returns over one year (152.11%) and three years (50.98%) have outpaced the BSE500 index, which recorded 6.48% and 35.92% respectively. The five-year return of 596.84% also significantly exceeds the index’s 91.52%. These figures underscore the company’s ability to deliver sustained value to shareholders over the long term.
Conclusion: A Milestone Reflecting Strong Fundamentals
The attainment of an all-time high price of Rs.1999 by Fredun Pharmaceuticals marks a significant milestone in the company’s market journey. Supported by robust financial results, consistent earnings growth, and favourable valuation metrics, the stock’s performance reflects a period of sustained strength within the Pharmaceuticals & Biotechnology sector. While institutional ownership remains limited, the company’s track record of positive quarterly results and capital efficiency continues to underpin its market standing.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
